HEPA Archives | BioTuesdays

Developments

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...

November 7, 2019

Developments

Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...

November 7, 2019

Markets

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

November 7, 2019

Developments

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit. Dr...

October 23, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Executive Moves

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is internationally known for...

October 10, 2019

Executive Moves

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...

October 3, 2019

Developments

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...

August 14, 2019

Executive Moves

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA). Dr. Harrison is a visiting professor of hepatology at the Radcliffe...

August 7, 2019

Developments

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...

July 31, 2019

Tag - HEPA

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion CRV431 reduces fibrosis in new model of NASH

Roth starts Hepion Pharma at buy; PT $9

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Follow Us

Subscribe

General

More

Subscribe